The FDA approved elinzanetant, a nonhormonal therapy for menopausal hot flashes and night sweats, following multinational clinical trials showing symptomatic benefit. Regulators granted the new drug clearance that provides a hormone‑free option for vasomotor symptom management. The approval expands the treatment toolbox for women’s health and adds a novel mechanism to an area historically dominated by estrogen‑based approaches. Clinical centers and prescribers will monitor longer‑term safety and real‑world uptake.